Position statement of the Latin American Federation of Climacteric and Menopause Societies (FLASCYM) regarding the use of Bioidentical Hormonal Compounds during female mid-life
Introduction Menopause hormone therapy (MHT) is the best option for the management of vasomotor symptoms, the genitourinary syndrome of menopause (GSM) and the prevention of bone loss [1]. However, in 2002, the preliminary publishing of data of the combined arm estrogen progestogen (E+P) of the Women Health Initiative study (WHI) reporting that women users of […]